Portugal’s SINACC Access Reform, built around the Sistema Nacional de Acesso a Consulta e Cirurgia, began as a straightforward technical upgrade. Its postponement has instead become a revealing test of how a national health system weighs digital goals against clinical and economic realities. The Ordem dos Médicos welcomed the delay as prudent, yet the conditions it set highlight structural issues that directly affect pricing, reimbursement and budget planning. Professionals in health economics and market access should treat the pause as a prompt to examine the data foundations more closely.

Why the pause points to deeper structural problems

The platform was created under Decreto-Lei n.º 12/2026 to centralise waiting lists for specialist consultations, planned surgery and therapeutic procedures, enforce maximum response times, and prepare for greater patient choice. Pilot work began in 2025. By mid-2026 the Ordem dos Médicos had flagged incomplete manuals, insufficient training, errors in coding and nomenclature, and the removal of some minor procedures from the formal surgical waiting list. Provisional figures put 278,394 patients still waiting, almost a third of them beyond 180 days. The Direção Executiva do SNS expanded testing rather than forcing a national launch, while the Ministry of Health agreed to review how minor surgery is defined and held firm on extra production rules. Flawed data at this layer distorts every later calculation of capacity, priority and cost.

Consequences for value assessment and resource signals

When coding tables fail to reflect clinical complexity, the metrics feeding health economics models become unreliable. Reclassifying minor procedures shrinks the visible lists, which risks presenting an improved access picture that does not match what patients actually experience. Market access teams that build budget impact projections or outcomes-based agreements then work from denominators that no longer capture true unmet need. The system also shifts unevenly: centres with mature information systems move ahead while others lag, and that territorial gap shows up later as higher downstream treatment costs and unequal access to surgery and innovative medicines alike. Value-based pricing arguments weaken if payers cannot trust the waiting-time and pathway data used to show that a new therapy shortens delay or prevents deterioration. Reimbursement decisions built on that data carry the same problem.

Pricing strategies and reimbursement under uncertainty

For pricing strategists, the immediate lesson is that the quality of access infrastructure is now a core pricing assumption. Companies preparing launches should model residual uncertainty in list integrity until independent clinical-technical validation is complete. Health technology assessment bodies that rely on national waiting-list statistics to rank priorities or set managed entry terms face a credibility gap. If minor procedures vanish from monitored tallies, apparent theatre capacity for complex cases may turn out to be illusory, changing incremental cost-effectiveness ratios and the affordability envelope for new interventions. Budget impact analyses that ignore this risk will mis-state both short-term savings and long-term liabilities. The SINACC Access Reform therefore forces a recalibration of how much weight evidence of system readiness carries next to clinical evidence in reimbursement decisions.

Actionable steps for decision-makers

HEOR and market access directors should require that future performance dashboards keep reclassified procedures fully visible, and that these data feed horizon scanning and budget impact models without loss of aggregation. Pricing teams should build scenario analyses that quantify the economic cost of continued delay against the efficiencies a properly validated platform could unlock, then adjust value dossiers to match. The Ministry of Health and Direção Executiva do SNS should turn the Ordem dos Médicos’ offer of collaboration into a formal joint validation programme covering specialty coding, training curricula, operational manuals and contingency protocols, before any new national deadline is set. Payers and assessment agencies should treat transparent pathway traceability as a precondition for confident reimbursement decisions, not an optional technical detail. Hospital leaders need to protect extra production capacity while the corrected system is proven, because clearing the backlog and fixing data integrity are complementary rather than sequential. Together these steps align digital modernisation with the evidentiary standards already applied to therapeutic innovation.

Sustaining confidence beyond technical go-live

SINACC Access Reform will succeed only if patient safety, clinical priority and a genuine reduction in waiting times come before rapid deployment targets. The current extended testing phase offers a narrow window to correct coding gaps, finish training and restore full traceability. Leaders who use that window to embed solid governance will strengthen the foundations for efficient resource allocation and credible value-based pricing. Those who treat the delay as a temporary inconvenience risk embedding distorted signals that undermine market access and erode professional and public trust. Continued structured dialogue among clinicians, coders, payers and industry, anchored in shared data standards, remains essential. The goal is an access architecture that supports accurate health economics and fair reimbursement decisions, and that stays sustainable over time.

Frequently Asked Questions

What is the SINACC Access Reform intended to achieve?

It aims to centralise waiting lists for specialist consultations, surgery and therapeutic procedures while enforcing maximum response times and supporting greater patient choice across the national health service.

Why was the national rollout of SINACC delayed?

Incomplete training materials, coding errors, missing operational manuals and questions over how minor procedures are classified led the Ordem dos Médicos and health authorities to extend testing rather than launch nationwide.

How does the delay affect pricing and reimbursement decisions?

Unreliable waiting-list data weakens the evidence base for budget impact models, value-based pricing arguments and health technology assessments, forcing companies and payers to build extra uncertainty into their calculations until the platform is fully validated.